{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:16:13Z","timestamp":1789474573325,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1124\/jpet.122.001318","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T12:26:58Z","timestamp":1667219218000},"page":"155-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effects of 2,5-Dimethoxy-4-Methylamphetamine (DOM) and 2-Piperazin-1-yl-Quinoline (Quipazine) on Fentanyl Versus Food Choice in Rhesus Monkeys"],"prefix":"10.1016","volume":"384","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0958-5397","authenticated-orcid":false,"given":"David R.","family":"Maguire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.122.001318_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.tips.2016.11.002","article-title":"Insights from preclinical choice models on treating drug addiction","volume":"38","author":"Banks","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.122.001318_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neuropharm.2018.02.018","article-title":"Psychedelics: where we are now, why we got here, what we must do","volume":"142","author":"Belouin","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.122.001318_bib3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/mol.54.1.94","article-title":"Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus","volume":"54","author":"Berg","year":"1998","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.122.001318_bib4","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00213-004-1891-x","article-title":"Self-administration of fentanyl, cocaine and ketamine: effects on the pituitary-adrenal axis in rhesus monkeys","volume":"176","author":"Broadbear","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.122.001318_bib5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0022-3565(25)33038-7","article-title":"A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist","volume":"221","author":"Colpaert","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001318_bib6","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0022-3565(25)39117-2","article-title":"Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors","volume":"242","author":"Conn","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001318_bib7","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1021\/acschemneuro.0c00291","article-title":"Psychedelic-like properties of quipazine and its structural analogues in mice","volume":"12","author":"de la Fuente Revenga","year":"2021","journal-title":"ACS Chem Neurosci"},{"key":"10.1124\/jpet.122.001318_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/14737175.2016.1220834","article-title":"Psilocybin for treating substance use disorders?","volume":"17","author":"de Veen","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"10.1124\/jpet.122.001318_bib9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/BF00405254","article-title":"Self-administration of psychoactive substances by the monkey","volume":"16","author":"Deneau","year":"1969","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.122.001318_bib10","doi-asserted-by":"crossref","first-page":"9791","DOI":"10.1007\/s11033-020-06009-x","article-title":"Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review","volume":"47","author":"DiVito","year":"2020","journal-title":"Mol Biol Rep"},{"key":"10.1124\/jpet.122.001318_bib11","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/17512433.2018.1511424","article-title":"Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews","volume":"11","author":"Dos Santos","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1124\/jpet.122.001318_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00008877-200403000-00007","article-title":"Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys","volume":"15","author":"Fantegrossi","year":"2004","journal-title":"Behav Pharmacol"},{"key":"10.1124\/jpet.122.001318_bib13","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0022-3565(25)21881-X","article-title":"Discriminative stimulus properties of quipazine: mediation by serotonin2 binding sites","volume":"228","author":"Friedman","year":"1984","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001318_bib14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/09540261.2018.1486289","article-title":"Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions","volume":"30","author":"Garcia-Romeu","year":"2018","journal-title":"Int Rev Psychiatry"},{"key":"10.1124\/jpet.122.001318_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108991","article-title":"Effects of buprenorphine\/lorcaserin mixtures on preference for heroin, cocaine, or saline over food using a concurrent choice procedure in rhesus monkeys","volume":"227","author":"Gerak","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.122.001318_bib16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0014-2999(83)90464-8","article-title":"Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists","volume":"91","author":"Glennon","year":"1983","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.122.001318_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.vascn.2016.07.004","article-title":"An intravenous self-administration procedure for assessing the reinforcing effects of hallucinogens in nonhuman primates","volume":"82","author":"Goodwin","year":"2016","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1124\/jpet.122.001318_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107933","article-title":"Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species","volume":"167","author":"Halberstadt","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.122.001318_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuropharm.2018.01.049","article-title":"Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans","volume":"142","author":"Heal","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.122.001318_bib20","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0022-3565(25)30082-0","article-title":"Negative reinforcing properties of some psychotropic drugs in drug-naive rhesus monkeys","volume":"192","author":"Hoffmeister","year":"1975","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001318_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.122.001318_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2021.797217","article-title":"Blockade of 5-hydroxytryptamine 2A receptor attenuates precipitation of naloxone-induced withdrawal symptoms in opioid-exposed mice","volume":"15","author":"Li","year":"2022","journal-title":"Front Behav Neurosci"},{"key":"10.1124\/jpet.122.001318_bib23","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/npp.2010.232","article-title":"Effects of direct- and indirect-acting serotonin receptor agonists on the antinociceptive and discriminative stimulus effects of morphine in rhesus monkeys","volume":"36","author":"Li","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.122.001318_bib24","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1124\/jpet.107.130625","article-title":"Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys","volume":"324","author":"Li","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001318_bib25","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1124\/jpet.108.145458","article-title":"Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys: antagonism and apparent pA2 analyses","volume":"328","author":"Li","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001318_bib26","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00213-012-2870-2","article-title":"Modification of the behavioral effects of morphine in rats by serotonin 5-HT1A and 5-HT2A receptor agonists: antinociception, drug discrimination, and locomotor activity","volume":"225","author":"Li","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.122.001318_bib27","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1007\/s00213-018-4932-6","article-title":"Reinforcing effects of opioid\/cannabinoid mixtures in rhesus monkeys responding under a food\/drug choice procedure","volume":"235","author":"Maguire","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.122.001318_bib28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1124\/jpet.122.001233","article-title":"Effects of daily methocinnamox treatment on fentanyl self-administration in rhesus monkeys","volume":"382","author":"Maguire","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001318_bib29","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/s41386-020-0698-8","article-title":"Effects of acute and repeated treatment with methocinnamox, a mu opioid receptor antagonist, on fentanyl self-administration in rhesus monkeys","volume":"45","author":"Maguire","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.122.001318_bib30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1124\/jpet.118.252353","article-title":"Long-lasting effects of methocinnamox on opioid self-administration in rhesus monkeys","volume":"368","author":"Maguire","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001318_bib31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00213-012-2803-0","article-title":"Effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) and quipazine on heroin self-administration in rhesus monkeys","volume":"225","author":"Maguire","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.122.001318_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12926","article-title":"Effects of 5-HT2A receptor stimulation on economic demand for fentanyl after intermittent and continuous access self-administration in male rats","volume":"26","author":"Martin","year":"2021","journal-title":"Addict Biol"},{"key":"10.1124\/jpet.122.001318_bib33","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s00213-005-2266-7","article-title":"Effects of punishment on choice between cocaine and food in rhesus monkeys","volume":"181","author":"Negus","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.122.001318_bib34","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1037\/a0013088","article-title":"Micro\/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability","volume":"16","author":"Negus","year":"2008","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1124\/jpet.122.001318_bib35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cpt.557","article-title":"Psychedelics as medicines: an emerging new paradigm","volume":"101","author":"Nichols","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.122.001318_bib36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cell.2020.03.020","article-title":"Psychedelic psychiatry\u2019s brave new world","volume":"181","author":"Nutt","year":"2020","journal-title":"Cell"},{"key":"10.1124\/jpet.122.001318_bib37","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3389\/fphar.2016.00514","article-title":"Blockade of serotonin 5-HT2A receptors suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-treated mice","volume":"7","author":"Pang","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1124\/jpet.122.001318_bib38","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0022-3565(25)22189-9","article-title":"Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis","volume":"246","author":"Sanders-Bush","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001318_bib39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1037\/pha0000253","article-title":"Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats","volume":"27","author":"Sakloth","year":"2019","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1124\/jpet.122.001318_bib40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3758\/BF03334456","article-title":"DMT self-administration by monkeys in isolation","volume":"16","author":"Siegel","year":"1980","journal-title":"Bull Psychon Soc"},{"key":"10.1124\/jpet.122.001318_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.108988","article-title":"Sex-specific role for serotonin 5-HT2A receptor in modulation of opioid-induced antinociception and reward in mice","volume":"209","author":"Sierra","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.122.001318_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108348","article-title":"A synthetic opioid vaccine attenuates fentanyl-vs-food choice in male and female rhesus monkeys","volume":"218","author":"Townsend","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.122.001318_bib43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0028-3908(80)90131-8","article-title":"Head twitches induced by LSD and quipazine: similarities and differences","volume":"19","author":"Vetulani","year":"1980","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.122.001318_bib44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0028-3908(79)90054-6","article-title":"Discriminative stimulus properties of quipazine: direct serotonergic mediation","volume":"18","author":"White","year":"1979","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.122.001318_bib45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0376-8716(86)90004-9","article-title":"Intravenous self-administration of (-)-cathinone and 2-amino-1-(2,5-dimethoxy-4-methyl)phenylpropane in rhesus monkeys","volume":"17","author":"Yanagita","year":"1986","journal-title":"Drug Alcohol Depend"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524003823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524003823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.122.001318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:17:36Z","timestamp":1739971056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524003823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0022356524003823"],"URL":"https:\/\/doi.org\/10.1124\/jpet.122.001318","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of 2,5-Dimethoxy-4-Methylamphetamine (DOM) and 2-Piperazin-1-yl-Quinoline (Quipazine) on Fentanyl Versus Food Choice in Rhesus Monkeys","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.122.001318","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}